|
Basic Characteristics of Mutations
|
|
Mutation Site
|
G118R |
|
Mutation Site Sentence
|
Of 17 resistance tests, 8 showed major mutations, including G118R and E138K. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
IN |
|
Standardized Encoding Gene
|
gag-pol:155348
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
HIV Infections
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
Y |
|
Treatment
|
INSTIs |
|
Location
|
Mozambique |
|
Literature Information
|
|
PMID
|
39885593
|
|
Title
|
Brief communication: virological outcomes and dolutegravir resistance mutations in HIV-infected patients: a multicenter retrospective cohort study in Mozambique
|
|
Author
|
Doro Altan AM,Majid N,Orlando S,Uamusse E,Rafael M,Sidumo Z,Guidotti G,Ciccacci F
|
|
Journal
|
AIDS research and therapy
|
|
Journal Info
|
2025 Jan 30;22(1):8
|
|
Abstract
|
The global HIV epidemic remains a major public health challenge, with DTG playing a key role in ART regimens due to its efficacy and tolerability. This study evaluated virological outcomes and resistance mutations in patients on DTG in Mozambique through a retrospective cohort study in seven DREAM centers. Data from 29,601 patients (98.1% on DTG) revealed a virological suppression rate of 95% (27,622/29,051). Factors positively associated with suppression included age > 50, longer ART duration, and being female. Of 17 resistance tests, 8 showed major mutations, including G118R and E138K. Results highlight DTG's effectiveness and the need for resistance surveillance.
|
|
Sequence Data
|
-
|